. 2020 Mar 12;38(5):1580–1587. doi: 10.1007/s10637-020-00914-5

Table 4.

Hemostatic response and effect on tumor perfusion after administration of dDAVP

Group	Hemostatic Response^a		Reduction of tumor perfusion^b
Group	PR + CR	CR	Reduction of tumor perfusion^b
Dose level 1 Dose level 2 Dose level 3 Dose level 4 Dose level 5	3/3 (100) 3/3 (100) 5/6 (83) 5/6 (83) NE^c	2/3 (67) 3/3 (100) 4/6 (67) 5/6 (83) NE^c	2/3 (67) 1/3 (33) 4/6 (67) 4/6 (67) NE^c
Expansion cohort	11/12 (92)	7/12 (58)	8/12 (67)
Total	27/30 (90)	21/30 (70)	19/30 (63)

^aRectal bleeding was graded as absent, mild, moderate and severe. Responses were evaluated at day 4 after treatment initiation and/or at the last follow-up at day 14, as described in Methods section. ^bPerfusion of rectal tumors was evaluated by DCE-RMI at day 4 after treatment initiation, considering AUC as the main parameter of reduction. ^cNot evaluated, since the two patients included in this group rapidly developed SAE and treatment was discontinued. Data presented as n/total (%).